.52
  Price3.33%   -0.0179
(After Hours: .53 +0.0100 +1.92%)
Aug-12-22 04:20AM Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From YesterdayBenzinga
Aug-11-22 10:11AM Athenex, Inc. 宣佈 3,000 萬美元公開發行普通股和認股權證GlobeNewswire Inc.
02:47AM Nasdaq Turns Lower; Crude Oil Rises SharplyBenzinga
Aug-11-22 01:49AM Why Matterport Is Trading Higher By Around 25%, Here Are 73 Stocks Moving In Thursday's Mid-Day SessionBenzinga
07:33AM Athenex, Inc. 宣佈擬議承銷公開發行普通股和認股權證GlobeNewswire Inc.
Aug-11-22 07:17AM Why Is Disney Higher By More Than 7%: Here Are 40 Stocks Moving PremarketBenzinga
04:21AM Athenex, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and WarrantsGlobeNewswire Inc.
Aug-08-22 03:05AM Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From FridayBenzinga
Aug-05-22 03:06AM Nasdaq Falls Over 100 Points, Marker Therapeutics Shares Spike HigherBenzinga
12:53PM Why Cooper-Standard Is Trading Higher By 70%, Here Are 81 Stocks Moving In Friday's Mid-Day SessionBenzinga
Aug-05-22 07:35AM Why Is Marker Therapeutics Trading Higher By 119%: Here Are 42 Stocks Moving PremarketBenzinga
06:00AM Penny Stocks to Buy Premarket on August 5th? 3 to Watch PennyStocks
May-11-22 03:56AM Athenex 提供 2022 年第一季度財務業績和業務更新GlobeNewswire Inc.
May-10-22 09:55AM Athenex (ATNX) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research
09:23AM The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO LeavesBenzinga
May-05-22 05:25AM Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research
Apr-29-22 08:00AM Athenex to Provide Corporate and Financial Update for the First Quarter 2022 on May 10, 2022GlobeNewswire Inc.
Apr-28-22 03:02AM Athenex (ATNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research
Mar-17-22 07:44AM Athenex 提供 2021 年第四季度及該年全年度財務業績並提供業務更新GlobeNewswire Inc.
Mar-16-22 04:10AM Athenex Provides Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateGlobeNewswire Inc.
Mar-15-22 07:46AM The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer TrialBenzinga
Mar-14-22 08:00AM CORRECTION: Athenex to Provide Corporate and Financial Update for the Fourth Quarter and Full Year 2021, on March 16, 2022GlobeNewswire Inc.
Mar-07-22 08:00AM Athenex 將在 2022 年 3 月 15 日為 2021 年第四季度及該年全年度提供企業及財務更新GlobeNewswire Inc.
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is under development to treat lung, ovarian, and cervical cancer; and oral eribulin co-administered with HM30181A that is under pre-clinical development to treat certain patients with breast cancer and advanced liposarcom. In addition, the company offers Src Kinase product candidates comprising KX-01, a compound, which is in Phase 3 study for the treatment of actinic keratosis; and KX-02 that is Phase I clinical trial for solid tumor patients. Further, it is developing intranasal formulations of granisetron, a 5-hydroxytryptamine 3 receptor antagonist to prevent chemotherapy-induced nausea and vomiting; and dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. has a strategic partnership with Hanmi Pharmaceuticals to develop their Orascovery and KX-01 programs. The company was founded in 2003 and is headquartered in Buffalo, New York.
Cap:    |  Volume (24h):